APOA1 and cardiovascular disorder: Studies on smoking cessation with varenicline have revealed significant reductions in LDL-C levels [32], along with decreases in oxidized high-density lipoprotein (oxHDL) levels—a potential marker for cardiovascular diseases—coupled with significant increases in HDL-C and improvements in serum apolipoprotein apoA-I levels in the short term [33,34].